维普期刊资源整合服务平台（V6.5）

22篇 您的检索式：作者名="TIBES R"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Activity of alemtuzumab in patients with CD52-positive acute leukemia 显示文摘	Tibes R Keating M J Ferrajoli A	2006	Cancer2006，106，12：	1
2	JAK-2 inhibitors in the treatment of myeloproliferative neoplasms显示文摘	Tibes R Bogenberger JM Geyer HL		0，，12：	1
3	Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma显示文摘	AMIN S H TIBES R KIM J E	2010	Laryngoscope2010，120，12：	1
4	JAK 2 inhibitors and their impact in myeloproliferative neoplasms 显示文摘	Geyer HL Tibes R Mesa RA	2012	Hematology2012，17，：	1
5	Prospective feasibilityanalysis of reduced-intensity conditioning(RIC)regimens forhematopoietic stem cell transplantation(HSCT)in elderlypatients with acute myeloid leukemia(AML)and high-riskmyelodysplastic syndrome(MDS)显示文摘	Estey E de Lima M Tibes R	2007	Blood2007，109，4：	1
6	Activity of alemtuzumab in patients with CI)52 positive acute leu-kemia显示文摘	TIBES R KEATING M J FERRAJOLI A	2006	Cancer2006，106，：	1
7	Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics 显示文摘	Tibes R Trent J Kurzrock R	2005	Annu Rev Pharmacol Toxicol2005，45，：	1
8	Activity of alemtuzumab in patients with CD52 - positive acute leukemia 显示文摘	Tibes R Keating MJ Ferrajoli A	2007	J Clin Oncol2007，25，35：	1
9	Activity of alemtuzumab in patients with CD52 - positive acute leukemia 显示文摘	Tibes R Keating M J Ferrajoli A	2006	Cancer2006，106，12：	1
10	Long-term safety, tolerability, and ef- ficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome显示文摘	Weiss GJ Tibes R Blaydom L	2011	Dermatol Reports2011，3，3：	1
11	Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias 显示文摘	Tibes R McDonagh KT Lekakis L	2015	Invest New Drugs2015，33，2：	1
12	Emerging drugs for polycythemia vera显示文摘	Tibes R Mesa RA	2013	Expert Opin Emerg Drugs2013，18，3：	1
13	Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietie stem cell transplantation(HSCT) in elderly patients with acute mye- loid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)显示文摘	Estey E de Lima M Tibes R	2007	Blood2007，109，4：	1
14	Prospective feasibility analysis of reduced-intensity conditioning (RIC) regi- mens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) 显示文摘	Estey E de Lima M Tibes R	2007	Blood2007，109，4：	1
15	Activity ofalemtuzumab in patients with CD52-positive acuteleukemia显示文摘	Tibes R Keating MJ Ferrajoli A	2006	Cancer2006，106，12：	1
16	Activity of alemtuzumab in patients with CD52-positive acute leukemia显示文摘	Tibes R Keating MJ Ferrajoli A		0，，：	1
17	Activity of alemtuzumab in patients with CD52-positive acute leukemia 显示文摘	Tibes R Keating M J Ferrajoli A	2006	Cancer2006，106，12：	1
18	Prospective feasi-bility analysis of reduced-intensity conditioning ( RIC)regimens for hematopoietic stem cell transplantation(HSCT) in elderly patients with acute myeloid leukemia(AML) and high-risk myelodysplastic syndrome ( MDS)显示文摘	Estey E de Lima M Tibes R	2007	Blood2007，109，4：	1
19	Activity of alemtuzumab in patients with CD52-positive acute leukemia显示文摘	Tibes R Keating MJ Ferrajoli A et aI	2006	Cancer2006，106，12：	1
20	PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation显示文摘	Tibes R Kornblau SM Qiu Y		0，，3：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示